N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Sponsor: Eli Lilly and Company • ClinicalTrials.gov ID: NCT07533019

Registry updated: 2026-10-08
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.

Interventions

  • LY4005130 (Drug)
    Administered IV
  • Placebo (Drug)
    Administered IV

Eligibility criteria

Inclusion Criteria: * Eligible participants must have the following at both screening and baseline: * A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months * Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet * BSA involvement of ≥0.5% on the face * F-VASI ≥0.5 and T-VASI ≥3, and * Either active or stable disease at both screening and baseline Exclusion Criteria: * Participants who have other types of vitiligo that are not considered active or stable vitiligo * Currently have active forms of other disorders of pigmentation * Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment * Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved * Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening * Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data * Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve

Conditions

Vitiligo Non-Segmental Vitiligo (NSV)

Locations

  • Medical Dermatology Specialists — Phoenix, Arizona, United States
  • Saguaro Dermatology - Phoenix — Phoenix, Arizona, United States
  • Center For Dermatology Clinical Research, Inc. — Fremont, California, United States
  • Northridge Clinical Trials — Northridge, California, United States
  • Cura Clinical Research - Oxnard — Oxnard, California, United States
  • Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway — Santa Clarita, California, United States
  • Health Clinical Research, LLC — Miami, Florida, United States
  • K2 Medical Research - Tampa — Tampa, Florida, United States
  • Advanced Medical Research, PC. — Sandy Springs, Georgia, United States
  • Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
  • Brigham and Women's Hospital — Boston, Massachusetts, United States
  • Revival Research Institute, LLC — Troy, Michigan, United States
  • Stracskin — Portsmouth, New Hampshire, United States
  • Equity Medical — The Bronx, New York, United States
  • Accurate Clinical Research, Inc — Humble, Texas, United States
  • Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue — San Antonio, Texas, United States
  • Jordan Valley Dermatology & Research Center — South Jordan, Utah, United States
  • Clinical Research Partners, LLC — Richmond, Virginia, United States
  • Anima Diepenbeek — Diepenbeek, Belgium
  • UZ Gent — Ghent, Belgium
  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman — Liège, Belgium
  • INTERMED Groupe Sante — Chicoutimi, Canada
  • DermEffects — London, Canada
  • Dar Clinical Research - Ottawa - Hunt Club Road — Ottawa, Canada
  • The Centre for Dermatology — Richmond Hill, Canada
  • Research Toronto — Toronto, Canada
  • SIMa Recherche — Verdun, Canada
  • Peking University People's Hospital — Beijing, China
  • Hangzhou Third People's Hospital — Hangzhou, China
  • Shanghai Skin Disease Hospital — Shanghai, China
  • The University of Hong Kong-Shenzhen Hospital — Shenzhen, China
  • Centrum Badan Klinicznych PI-House sp. z o.o. — Gdansk, Poland
  • Diamond Clinic — Krakow, Poland
  • Dermedic Jacek Zdybski — Ostrowiec Świętokrzyski, Poland
  • Centrum Medyczne Ginemedica — Wroclaw, Poland
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record